Thyroid Eye Disease TED: 101 New Drug
Teprotumumab for Thyroid-Associated Ophthalmopathy
N Engl J Med 2017; 376:1748-1761May 4, 2017
Thyroid-associated ophthalmopathy, a condition commonly associated with Graves’ disease, remains inadequately treated.
In patients with active ophthalmopathy, teprotumumab was more effective than placebo in reducing proptosis and the Clinical Activity Score.
Comment:This appears to be a great new asset in the treatment of TED. Time will tell of course.
In practice since 1974 as a thyroidologist I have seen a decline in TED with Graves’ hyperthyroidism since the incidence of smoking has decreased. The bad eyes in the smoking era was common but now it is less frequent. Even the thyroid eye surgeons have seen a decrease and have switched to oculo-plastic work.
Richard Guttler MD,FACE,ECNU